Phase I study of weekly maytansine given by iv bolus or 24-hour infusion
Chahinian, A.P.; Nogeire, C.; Ohnuma, T.; Greenberg, M.L.; Sivak, M.; Jaffrey, I.S.; Holland, J.F.
Cancer Treatment Reports 63(11-12): 1953-1960
1979
ISSN/ISBN: 0361-5960 PMID: 526928 Document Number: 151675
Document emailed within 1 workday
Related Documents
Ohnuma, T.; Norton, L.; Andrejczuk, A.; Holland, J.F. 1985: Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans Cancer Research 45(1): 464-469Grunberg, S.M.; Kempf, R.A.; Venturi, C.L.; Mitchell, M.S. 1987: Phase i study of recombinant beta-interferon given by four-hour infusion Cancer Research 47(4): 1174-1178
Lomen, P.L.; Baker, L.H.; Neil, G.L.; Samson, M.K. 1975: Phase i study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days Cancer ChemoTherapy Reports 59(6): 1123-1126
Akerley, W.; Glantz, M.; Choy, H. 1996: Preliminary results of a phase i study of weekly paclitaxel infusion in patients with non-small cell lung cancer Seminars in Oncology 23(5 Suppl 12: 14-18
Seidman, A.D. 1998: One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index Oncology 12(1 Suppl 1: 19-22
Seidman, A.D.; Hudis, C.A.; McCaffrey, J.; Tong, W.; Currie, V.; Moynahan, M.E.; Theodoulou, M.; Tepler, I.; Gollub, M.; Norton, L. 1997: Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer Seminars in Oncology 24(5 Suppl 17: S17
Weiss, G.R.; Ervin, T.J.; Meshad, M.W.; Kufe, D.W. 1982: Phase Ii trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU Cancer Treatment Reports 66(2): 299-303
Huang, W.Tsung.; Chang, K.Chao.; Shan, Y.Shen.; Tsao, C.Jung.; Lee, J.Chang. 2005: Successful initial treatment with weekly 24-hour infusion of 5-fluorouracil and leucovorin in a rectal cancer patient with acute disseminated intravascular coagulation Hepato-Gastroenterology 52(65): 1436-1439
Roychowdhury, D.F.; Desai, P.; Zhu, Y.W. 1997: Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase Ii study in advanced non-small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12
Edmonson, J.H.; Hahn, R.G.; Creagan, E.T.; O'Connell, M.J. 1983: Phase II study of maytansine in advanced sarcomas Cancer Treatment Reports 67(4): 401-402
Edmonson, J.H.; Rubin, J.; Kvols, L.K.; O'Connell, M.J.; Frytak, S.; Green, S.J. 1981: Phase II study of maytansine in advanced breast cancer Cancer Treatment Reports 65(5-6): 536-537
Rosenthal, S.; Harris, D.T.; Horton, J.; Glick, J.H. 1980: Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 64(10-11): 1115-1117
Greco, F.A.; Hainsworth, J.D. 1995: One-hour paclitaxel infusion schedules: a phase I/Ii comparative trial Seminars in Oncology 22(3 Suppl 6: 118-123
Mross, K.; Bewermeier, P.; Reifke, J.; Krüger, W.; Stockschläder, M.; Zander, A.; Hossfeld, D.K. 1994: Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion Bone Marrow Transplantation 13(4): 423-430
Ratanatharathorn, V.; Gad-el-Mawla, N.; Wilson, H.E.; Bonnet, J.D.; Rivkin, S.E.; Mass, R. 1982: Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study Cancer Treatment Reports 66(7): 1687-1688
Remick, S.C.; Grem, J.L.; Fischer, P.H.; Tutsch, K.D.; Alberti, D.B.; Nieting, L.M.; Tombes, M.B.; Bruggink, J.; Willson, J.K.; Trump, D.L. 1990: Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion Cancer Research 50(9): 2667-2672
Hartjen, K.; Fischer, M.V.; Mewes, R.; Paravicini, D. 1996: Preventive pain therapy. Preventive tramadol infusion versus bolus application in the early postoperative phase Der Anaesthesist 45(6): 538-544
Müller, P.H.; Egberts, E.H.; Held, W.; Junger, K.; Schmülling, R.; Prestele, H.; Horbach, L.; Malchow, H. 1981: Carbohydrate infusion in internal diseases. a comparative study of metabolically healthy persons and liver disease and diabetic patients. III. Glucose infusion over a 48-hour period Infusionstherapie und Klinische Ernahrung 8(6): 266-269
Chang, A.Y.; Boros, L.; Asbury, R.; Hui, L.; Rubins, J. 1997: Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer Seminars in Oncology 24(5 Suppl 17: S17
Liesmann, J.; Belt, R.J.; Haas, C.D.; Hoogstraten, B. 1981: Phase I study on bruceantin administered on a weekly schedule Cancer Treatment Reports 65(9-10): 883-885